πŸ‡ΊπŸ‡Έ FDA
Patent

US 6630124

Combination therapy with VIP antagonist

expired A61KA61K31/351A61K31/427

Quick answer

US patent 6630124 (Combination therapy with VIP antagonist) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 07 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
47
CPC classes
A61K, A61K31/351, A61K31/427, A61K33/243, A61K38/14